Advanced Model for Evaluation of iPSCs Lung Engraftment
Tokalov SV1, Fleischer A1 and Bachiller D1,2*
1Fundación Caubet-Cimera, Development and Regeneration Program, Spain
2Consejo Superior de Investigaciones Científicas (CSIC), Spain
- Corresponding Author:
- Bachiller D
Fundación Caubet-Cimera, Development and Regeneration Program
Consejo Superior de Investigaciones Científicas (CSIC)
Ctra. Sóller Km 12, 07110 Bunyola (Balearic Islands), Spain
E-mail: [email protected]
Received Date: June 13, 2016; Accepted Date: July 04, 2016; Published Date: July 14, 2016
Citation: Tokalov SV, Fleischer A, Bachiller D (2016) Advanced Model for Evaluation of iPSCs Lung Engraftment. J Stem Cell Res Ther 6:350. doi:10.4172/2157-7633.1000350
Copyright: © 2016 Tokalov SV, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
a number of pathologies affecting different organs, including the lung. One of the main challenges affecting iPSCs based therapies is the low level of iPSCs engraftment. While the exact mechanisms by which systemically administrated iPSC might be recruited to lung remain poorly understood recent results show that their ability to engraft might not solely be a property of iPSC but might be caused by some events in recipients’ lungs, including modifications of some signaling pathways due to damage, repair or developmental processes. Engraftment of Infrared Fluorescent Protein (iRFP) expressing iPSCs (iRFP-iPSCs) into intact and damaged lung was investigated 2 weeks after hemithorax (HTI, right lung) irradiation with 0 (sham treated control), 10 and 20 Gy, or after intratracheal administration of bleomycin (BLM, 0.075U) to 8 weeks old mice and 1 day old intact pups. Location of iRFP-iPSCs was recorded in vivo, ex vivo during autopsy, in the dissected organs and in tissue sections 1 day and 1 week after iRFP-iPSCs administration. Increased enrollment of single iRFP-iPSCs into the both HTI and BLM challenged lungs was detected ex vivo and in the dissected organs and was also confirmed by histological examinations shortly after administration, but did not increase in time. In contrast, injection of iRFP-iPSCs to 1 day old intact pups allowed for robust lung uptake, as well as for the development of donor-derived iRFP-iPSCs colonies in lung, as was revealed 1 week after their transplantation. One day old pups represent an useful model in which to analyze iPSCs capture and engraftment in the lung.